JNJ-678 (JNJ-53718678) (Synonyms: JNJ-678; JNJ-53718678) |
| カタログ番号GC32297 |
JNJ-678 (JNJ-53718678) (JNJ-678) は、新規の融合タンパク質阻害剤です。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1383450-81-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
JNJ-678 (JNJ-53718678) is a novel fusion protein inhibitor in clinical trials for the treatment of respiratory syncytial virus (RSV).
JNJ-678 (JNJ-53718678) is a small-molecule respiratory syncytial virus (RSV) fusion inhibitor currently under clinical evaluation in infants hospitalized for RSV infection. JNJ-678 (JNJ-53718678) binds to RSV F protein in its prefusion conformation. JNJ-678 (JNJ-53718678) displays very potent antiviral activity and low cytotoxicity. In addition to its activity against the RSV A2 strain, JNJ-678 (JNJ-53718678) is also highly active against a number of RSV strains from both A and B subtypes. The EC50 in an RSV infection assay using HeLa cells is 460 pM[1].
Oral treatment of neonatal lambs with JNJ-678 (JNJ-53718678), or with an equally active close analog, efficiently inhibits established acute lower respiratory tract infection in the animals, even when treatment is delayed until external signs of respiratory syncytial virus illness have become visible[1].
[1]. Roymans D, et al. Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor. Nat Commun. 2017 Aug 1;8(1):167.
Average Rating: 5 (Based on Reviews and 4 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *